CB1/CNR1 Full-Length Membrane Proteins, ECD Proteins and Antibodies

The cannabinoid receptor type 1 (CB1), also known as CANN6, encoded by CNR1, is a class A G protein-coupled receptor and a central component of the endocannabinoid system. The seven-transmembrane receptor is highly expressed in the central nervous system, particularly in the cortex, hippocampus, basal ganglia, and cerebellum, with additional expression in peripheral tissues including liver, adipose tissue, and skeletal muscle. Endogenous ligands such as anandamide and 2-arachidonoylglycerol activate CB1 primarily through Gi/o proteins to regulate adenylyl cyclase, ion channels, and downstream signaling. Through these mechanisms, CB1 influences neurotransmitter release, pain perception, appetite, learning, mood, and metabolic homeostasis. CB1 remains an important research target in metabolic and liver diseases, fibrosis, pain, and neurological disorders, with increasing interest in approaches designed to modulate peripheral signaling while limiting central effects.

Because CB1 is a seven-pass GPCR, native conformation is highly dependent on the membrane environment. DIMA BIOTECH therefore provides full-length human CB1 in Synthetic Nanodisc and MNP formats, including biotinylated and alternative tagged versions, for native-conformation antibody screening, SPR/BLI, binding characterization, and specificity assessment. Human and mouse CB1 ECD proteins support ELISA and N-terminal epitope studies, while ELISA/flow cytometry-validated rabbit monoclonal antibodies, including PE- and biotin-conjugated formats, support cell-surface detection and antibody screening. DIMA has also established CB1 single B-cell and lead antibody resources for downstream functional evaluation and antibody engineering.